Eli Lilly and Company (NYSE:LLY) Shares Down 2.3% – Time to Sell?

Eli Lilly and Company (NYSE:LLY) shares fell 2.3% on Tuesday . The company traded as low as $1,034.81 and last traded at $1,038.2280. 2,568,851 shares changed hands during mid-day trading, a decline of 13% from the average session volume of 2,951,121 shares. The stock had previously closed at $1,062.75.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Pirtobrutinib Phase 1/2 trial completion signals progression in Lilly’s BTK inhibitor program—successful early-stage readouts and movement toward later-stage trials could add a new oncology growth driver. Eli Lilly’s Pirtobrutinib Trial Completion Signals Next Phase in the BTK Inhibitor Race
• Positive Sentiment: Oncology pipeline momentum and a reported $1B AI partnership with Nvidia (plus an FDA Breakthrough Therapy designation for sofetabart mipitecan) support longer‑term growth expectations and R&D productivity gains. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Positive Sentiment: Core commercial strength — heavy demand for Lilly’s GLP‑1 weight‑loss and diabetes drugs has driven a substantial share rally and positive analyst attention (debate now centers on valuation vs. growth runway). Up 36%, Is Eli Lilly Still a Buy?
• Neutral Sentiment: Investor interest and coverage remain high—Lilly is a trending stock across screens and retail interest, which can amplify short‑term volatility even absent new fundamentals. Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: New marketing that focuses on “weight stigma” reflects brand positioning amid increasing GLP‑1 competition; this is strategic but not an immediate earnings driver. Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’
• Negative Sentiment: Medicare selected several Lilly drugs for the next round of price negotiations (including the first Part B‑reimbursed products) — if negotiations lead to mandated price cuts, revenue and margin pressure could follow. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Hospital groups (AHA) are pushing back on Lilly’s new 340B claims‑data submission policy, asking regulators to block it — this creates regulatory friction and potential reputational/legal risk with provider customers. AHA urges HRSA to stop Eli Lilly’s 340B claims-data submission policy from going into effect

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. National Bankshares set a $1,286.00 target price on Eli Lilly and Company in a research report on Monday, December 1st. Scotiabank assumed coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price objective on the stock. Guggenheim decreased their target price on Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a report on Tuesday, January 20th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Wednesday, January 14th. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Four analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $1,174.61.

Eli Lilly and Company Stock Performance

The firm has a market capitalization of $981.52 billion, a price-to-earnings ratio of 50.79, a PEG ratio of 0.80 and a beta of 0.35. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock’s 50-day moving average is $1,057.99 and its 200-day moving average is $883.36.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the company posted $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 29.35%.

Hedge Funds Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $25,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in Eli Lilly and Company during the second quarter worth $27,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares during the last quarter. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $29,000. Finally, Steph & Co. lifted its stake in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after acquiring an additional 29 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.